However, other reports claim that insulin administration in COVID-19 patients worsened the clinical profile and was correlated with poor prognosis possibly due to the insulin-mediated inhibition of disintegrin and metalloproteinase domain–containing protein 17 (ADAM17), thereby facilitating the proteolytic cleavage and shedding of the active ecto-domain of ACE2 and thus increasing the availability and activity of ACE2 for SARS-CoV-2 infection [51,52]. The gene discussed is ACE2; the disease is COVID-19.